Latest Breaking News On - European thyroid association guidelines for the treatment - Page 3 : comparemela.com

Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results 1 Detailed results will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Participation in the collaboration will provide Ipsen with access to full trial data to support potential future regulatory submissions Disclaimer: Intended for international media and investor audiences only Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has exercised its option to collaborate with Exelixis, Inc. (Exelixis) in the pivotal COSMIC-311 Phase III trial. COSMIC-311 is evaluating Cabometyx (cabozantinib) 60 mg versus placebo in people living with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies.

France generalUnited statesHong kongUnited kingdomNew zealandSouth koreaDominican republicSaudi arabiaRussian federationGiovanni astaHoward mayerGemma roperIpsen euronextHead of researchAmerican society of clinical oncologyDrug administration